Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
27°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amarin Corporation plc
< Previous
1
2
3
Next >
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
March 05, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
ASX
CSLLY
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
February 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
February 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at Cowen's 43rd Annual Health Care Conference
February 22, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
February 21, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
February 17, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals
February 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
February 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals
February 13, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Shareholders Invited to Webcast with Board and Management Team
February 13, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals
February 09, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts
February 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
February 02, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
January 31, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
January 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at SVB Securities Global Biopharma Conference
January 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
January 19, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
January 11, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
January 10, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
January 10, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 14, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
December 07, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
November 15, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at Jefferies London Healthcare Conference
November 09, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
November 07, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.